Alphamab Oncology Competitors and Similar CompaniesClear all
Alphamab Oncology's competitors and similar companies include Syndax Pharmaceuticals, Immunomedics, X4 Pharmaceuticals and OSE Immunotherapeutics.
 Syndax Pharmaceuticals Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services. |  OSE Immunotherapeutics OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. | ||
Founding Date | Founding Date 2009 | Founding Date 2005 | Founding Date 1982 | Founding Date 2010 | Founding Date 2012 |
Type | Type Private | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Suzhou Shi, CN HQ | Locations Waltham, US HQ New York, US Waltham, US | Locations Morris Plains, US HQ | Locations Boston, US HQ Wien, AT | Locations Nantes, FR HQ Paris, FR |
Employees | Employees 42 | Employees 358% decrease | Employees 8914% decrease | Employees 1005% increase | Employees 52 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.6 b | Valuation ($) N/A | Valuation ($) 83.9 m | Valuation ($) 239 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $172.4m (FY, 2025) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) $6.5m (FY, 2025) | Revenue (est.) €69.9m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $5.8m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $295k (FY, 2019) | Gross profit $743k (FY, 2025) | Gross profit €83.4m (FY, 2024) |
Net income | Net income N/A | Net income ($285.4m) (FY, 2025) | Net income ($357.3m) (FY, 2019) | Net income N/A | Net income €37.4m (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 160m | Total funding raised N/A | Total funding raised $ 30m | Total funding raised $ 64.5m | Total funding raised $ 10.3m |
For sources of this data, please see the company profile
View Company Profiles
Syndax Pharmaceuticals
HQ
Waltham, US
Employees
35↓ 8% decrease
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
View companyImmunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyX4 Pharmaceuticals
HQ
Boston, US
Employees
100↑ 5% increase
X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
View companyOSE Immunotherapeutics
HQ
Nantes, FR
Employees
52
OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
View company